Sofinnova Partners — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Bioptimus is an AI-first biotech company developing a universal AI foundation model that connects biology across scales, from molecules and cells to tissues and whole organisms, to support biomedical research and innovation.
AI & Machine LearningBiotechDigital HealthHealthtechParis, FR
Eric Durand(Founder)Felipe Llinares-López(Co-founder & VP of AI)Rodolphe Jenatton(Co-founder & CTO)Zelda Mariet(Co-founder & VP of Research)Jean-Philippe Vert(Co-founder & CEO)inDavid Cahané(Co-founder & General Manager)
Co-investorsAndera PartnersCathay InnovationFELIX CAPITALFrstHeadlineHeadline Growth Management, LLC+3 more
Cure51 is a cancer research company that decodes the biology of exceptional cancer survivors ("cancer outliers") using molecular profiling and computational biology, collecting patient data on its Patient Profile Platform.
AI & Machine LearningBiotechDigital HealthHealthtech
Paloma Cejas(Founder, Head of Translational Research)Rémy Nicolle(Founder, Senior Advisor Computational Biology)
Co-investorsHitachi VenturesKima VenturesLifeX Ventures
Endoron Medical develops transcatheter anchoring and sealing devices for aortic procedures, including Aortodock (a nitinol docking system to stabilize transcatheter valves in low-calcium aortic regurgitation and stenosis anatomies) and Aortoseal (a multi-stapling fixation and sealing system for endovascular aneurysm repair grafts).
HardwareHealthtechMedical Devices
Purespring is a precision nephrology company developing podocyte-targeted gene therapies for kidney diseases, using its GlomThera platform to deliver genetic treatments directly to kidney cells.
BiotechHealthtechMedical Devices
Co-investorsBritish Patient CapitalForbionGilde Healthcare
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.